Show simple item record

dc.contributor.authorMurphy, JFA
dc.date.accessioned2013-10-17T16:48:16Z
dc.date.available2013-10-17T16:48:16Z
dc.date.issued2013-10
dc.identifier.urihttp://hdl.handle.net/10147/303553
dc.descriptionBexsero, a 4 component protein-based meningococcal B vaccine (4CMen B) manufactured by Novartis was authorised for use by the European Medicines1 in January 2013. The development of 4C Men B has taken long years of research because of the similarity between the serogroup B capsule and the human antigen neural-cell adhesion molecules. It necessitated a new approach called reverse vaccinology which involves whole-genome sequencing of bacteria and the identification of proteins that provoke an immunological response. The 4CMen B vaccine has 4 antigenic components. The clinical trials have involved 8000 children. One month after the third dose, 84-100 per cent had a satisfactory immunological response2. The new vaccine should protect against 73% of the strains that cause the disease. The recommended immunisation for infants is 3 doses commencing at 2 months with 2 further doses at least 1 month apart. For unvaccinated older children 2 doses are recommended. Since 1999 serogroup C conjugate vaccine has been available for the prevention of meningococcal C disease and has led to a dramatic reduction in the incidence of the disease.en_GB
dc.language.isoenen
dc.publisherIrish Medical Journal (IMJ)en_GB
dc.subjectMENINGITISen_GB
dc.subjectIMMUNISATIONen_GB
dc.titleMeningococcal B vaccineen_GB
dc.contributor.departmentIrish Medical Journal (IMJ)en_GB
dc.identifier.journalIrish Medical Journal (IMJ)en_GB
refterms.dateFOA2018-08-23T08:47:52Z


Files in this item

Thumbnail
Name:
Article7698.pdf
Size:
6.421Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record